Table 4.

Change in the AAD effects in the wild-type and PITX2^+/− deficiency groups.

	Overall				Wild type				PITX2+/− deficiency
	Class IC (n = 200)	Class III(n = 300)	p-value	Effect size	Class IC (n = 100)	Class III(n = 150)	p-value	Effect size	Class IC (n = 100)	Class III(n = 150)	p-value	Effect size
ΔAPD90 (ms)	34.1 ± 32.3	45.3 ± 55.3	0.010	0.246	33.7 ± 34.3	41.2 ± 38.9	0.124	0.202	34.5 ± 30.3	49.4 ± 67.7	0.040	0.284
ΔCV (m/s)	−0.14 ± 0.14	−0.20 ± 0.26	0.004	0.299	−0.14 ± 0.12	−0.16 ± 0.22	0.334	0.138	−0.14 ± 0.17	−0.25 ± 0.31	0.003	0.444
ΔMean Smax	0.102 ± 0.261	0.031 ± 0.250	0.003	0.277	0.041 ± 0.247	−0.020 ± 0.267	0.070	0.238	0.163 ± 0.262	0.082 ± 0.222	0.010	0.333
ΔMean AFCL (ms)	23.96 ± 28.62	35.69 ± 29.73	<0.001	0.402	19.37 ± 27.48	25.98 ± 20.72	0.075	0.271	29.40 ± 29.17	45.18 ± 33.97	0.002	0.498
ΔPeak DF (Hz)	−2.75 ± 4.85	−5.20 ± 4.80	<0.001	0.101	−0.87 ± 4.54	−4.38 ± 4.71	<0.001	0.759	−4.63 ± 4.42	−6.01 ± 4.75	0.022	0.301
ΔMean DF (Hz)	−1.38 ± 1.85	−2.53 ± 2.34	<0.001	0.547	−1.06 ± 1.80	−2.54 ± 2.64	<0.001	0.656	−1.70 ± 1.86	−2.53 ± 2.02	0.001	0.428
ΔPS number (n)	−25,537 ± 75,778	−38,584 ± 78,053	0.065	0.170	−48,492 ± 97,348	−66,541 ± 100,233	0.160	0.183	−2,583 ± 31,647	−10,626 ± 24,600	0.025	0.284
ΔPS life span (ms)	−20.04 ± 101.29	−41.85 ± 103.51	0.020	0.213	−6.00 ± 86.21	−37.45 ± 57.81	0.001	0.429	−34.07 ± 113.11	−46.25 ± 134.61	0.456	0.098

APD₉₀, action potential duration 90%; CV, conduction velocity; Smax, the maximal slope of the restitution curves; AFCL, AF cycle length; DF, dominant frequency; PS, phase singularity; Defragmentation, termination + AT conversion; n, number of patient ^*AAD^*dose.

Patients who did not maintain an AF status were excluded from the statistical analysis for the APD₉₀, CV, mean Smax, mean AFCL, and wave dynamics.